Choose smart money in health

4 reasons to raise funds with Angels Santé


Access our 150+ expert healthcare investors


Connect to our French and European healthcare ecosystem


Get active support throughout your business development


Connect to our French and European healthcare ecosystem


Become an exclusive member of the Angels Santé Family

How to be selected ?

  • Biotech : your PoC is at the regulatory preclinical stage (in vivo PoC completed)
  • Medtech : your prototype is finalized and ideally your first pilot studies have been carried out on a few patients,
  • Digital Health: your solution has been developed and is starting to gain commercial traction.

Tick all the boxes ?

Let's check your eligibility.

important to know

The Angels Santé fundraising process takes an average of 3 to 6 months from application to closing. Before applying, make sure you can anticipate this timeframe.

Our selection process


Submit your application on our Dealum platform

1 day
Pre-application eligibility check

According to our investment thesis

2 weeks
Selection committee

A one-hour meeting before validation to pitch

4 to 6 weeks
/1 to 1.5 month
Pitch to our investors

*210 € participation fee per company

8 to 12 weeks
/ 2 to 3 months
Due Diligence

( HR, IP, finance, contracts, négociation …)

4 weeks
1 month
pitch and investment

*4.5% Success fee


Discover our Portfolio Companies

, 2024
- Rennes
Winnove amélioree l’efficacité thérapeutique de la contention orthodontique et garantit le sourire de 34 millions de patients
Hephaistos Pharma
, 2023
- Paris

Hephaistos-Pharma is developing a new generation of immunostimulant to treat metastatic and hardly accessible tumors

Alga Therapeutics
, 2023
- Rouen

Alga Therpeutics produces cancer-fighting antibodies from micro-algae.

, 2023
- Nantes

Abcely develops innovative medical and pharmaceutical technologies for the treatment of mucosal cancers.

Bliss TX
, 2023
- Laval

A new generation of digital solutions for pain management throughout the patient journey.

Odimma Therapeutics
, 2023
- Strasburg

Odimma develops personalized immunotherapy using AI and synthetic DNA technology.